Aprea Therapeutics Launches $5.5 Million Stock Offering to Fund Revolutionary Therapies

Aprea Therapeutics, Inc. (Nasdaq: APRE) is excited to announce the pricing of its public offering of 1,050,000 shares of common stock at a public offering price of $5.25 per share. With this offering, the Company is expecting to raise approximately $5.5 million before deducting underwriting discounts and commissions and estimated offering expenses. Additionally, the underwriter has been given a 30-day option to purchase up to an additional 157,500 shares of common stock. This offering is a great opportunity for investors to get involved in a biopharmaceutical company focused on developing novel cancer therapeutics to target DNA damage response pathways.

The public offering of the Company will enable it to continue its journey towards developing its clinical asset, ATRN-119, and its pre-clinical asset ATRN-W1051, while also allowing for investments in general corporate operations. The proceeds will be an important step towards the Company’s long-term objectives and will ensure that progress is made on a number of exciting projects.

Maxim Group LLC is proud to serve as the sole book-running manager for this exciting offering. We are committed to making this process as smooth and successful as possible for all involved.

About Aprea Therapeutics

Aprea Therapeutics, Inc. is a pioneering biopharmaceutical company based in Doylestown, Pennsylvania, dedicated to creating groundbreaking cancer therapeutics. The company is focusing on leveraging the power of synthetic lethality to target core pathways in DNA Damage Response and cancer progression. Their lead product ATRN-119 is a clinical-stage small molecule ATR inhibitor, while a WEE1 inhibitor is also progressing towards IND submission. With their innovative approach, Aprea Therapeutics is revolutionizing the fight against cancer.

Leave a Comment